Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) has announced an upcoming investor webcast scheduled for Wednesday, March 19, 2025, at 8:00 AM ET. The presentation will focus on revealing results from two significant clinical trials: the Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial findings from the Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The webcast will feature presentations from Pete Salzmann, M.D., MBA, Immunovant's Chief Executive Officer, alongside Matt Gline, Chief Executive Officer of Roivant. Interested participants can access the live webcast through registration, and it will also be available in the News & Events section of Immunovant's website. A replay option will be provided immediately after the event.
Positive
- None.
Negative
- None.
News Market Reaction – IMVT
On the day this news was published, IMVT gained 0.48%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com
FAQ
When will Immunovant (IMVT) present its batoclimab Phase 3 MG study results?
What clinical trial results will IMVT discuss in the March 19 webcast?
How can investors access the IMVT March 19 webcast?
Who will be presenting at the IMVT investor webcast on March 19?
